baricitinib
Sign in to saveBaricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Key facts
- Drug.MedlinePlus
- a618033
- Drug.DailyMedID
- Baricitinib
- Drug.pregnancy_AU
- D
- Drug.pregnancy_category
- Use is contraindicated
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AF02
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 79%
- Drug.protein_bound
- 50%
- Drug.metabolism
- CYP3A4 (<10%)
- Drug.elimination_half life
- 12.5 hours
- Drug.excretion
- 75% urine, 20% faeces
- Drug.CAS_number
- 1187594-09-7
via Wikipedia infobox
Article
16 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Research
- Alopecia areata
- COVID-19
- HIV/AIDS
- References
- Further reading
Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Baricitinib is approved for medical use in the European Union and in the United States.